key: cord-0851330-v33e1qyq
authors: Kreitman, Robert J.; Arons, Evgeny
title: Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues
date: 2021-09-04
journal: Blood Rev
DOI: 10.1016/j.blre.2021.100888
sha: 4b635bb701080673489e478cb1c72b6d9e0ce32a
doc_id: 851330
cord_uid: v33e1qyq

Hairy cell leukemia (HCL) is an indolent B-cell malignancy, usually driven by the BRAF V600E mutation. For 30 years, untreated and relapsed HCL was successfully treated with purine analogs, but minimal residual disease (MRD) remained in most patients, eventually causing relapse. Repeated purine analogs achieve decreasing efficacy and increasing toxicity, particularly to normal T-cells. MRD-free complete remissions (CRs) are more common using rituximab with purine analogs in both 1(st)-line and relapsed settings. BRAF inhibitors and Ibrutinib can achieve remission, but due to persistence of MRD, must be used chronically to prevent relapse. BRAF inhibition combined with Rituximab can achieve high MRD-free CR rates. Anti-CD22 recombinant immunotoxin moxetumomab pasudotox is FDA-approved in the relapsed setting and is unique in achieving high MRD-free CR rates as a single-agent. Avoiding chemotherapy and rituximab may be important in ensuring both recovery from COVID-19 and successful COVID-19 vaccination, an area of continued investigation.

and bright positive for CD25, but they lack BRAF V600E. The disease in these patients is aggressive, is associated with nodal disease and responds poorly to first line purine analog. Thus IGHV4-34+ HCL/HCLv should be considered a molecularly defined variant which overlaps with HCLv 7,67-69 . A case of CLL transforming to HCLv was described in a patient with IGHV4-34+ leukemic cells 70 . While HCLv and IGHV4-34+ HCL/HCLv lacks BRAF V600E, we reported MA2PK1 mutations in about half of these patients, in addition to mutations in U2AF1, ARID1A, TP53 and TTN 71 . In several HCLv cases, Maitre et al. reported mutations in KDM6A and CREBBP, which like ARID1A are epigenetic regulatory genes 53 . Other mutated or deleted genes or regions in HCLv include CCND3, CCND1 (mutation and fusion with IgH), ATM, and 7p 6, 52, 72, 73 . Myf6 is a muscle-associated gene found to be expressed in essentially 100% of HCL classic cases and much less frequently in HCLv or IGHV4-34+ HCL 74 . Unusual markers in classic HCL like CD38 have been associated with shorter time to progression and next treatment 75 . Other aberrant markers like CD5 or CD10 have not shown prognostic implications [76] [77] [78] [79] .

A small minority of HCL patients can wait on treatment for years or decades. On the other hand, it is rare that treatment is so urgent that patients can't wait for several weeks or months. The most commonly accepted indications for treatment are neutrophils < 1-1.5 x 10 9 cells/L, hemoglobin <10-12 g/dL, and platelets <100 x10 9 cells/L 17, 19, 25, 80 . We and other groups favor the 1, 10, and 100 limits, respectively, in view of the toxicity of chemotherapy for HCL and wanting to avoid excessive retreatment 19, [81] [82] [83] [84] [85] [86] . Additional criteria for treatment include malignant lymphocytosis >5 or >20 x10 9 /L or progressing lymphocytosis, symptomatic splenomegaly or hepatomegaly, enlarging lymph nodes >2cm in short axis, frequent infections, and unexplained weight loss >10% in the prior 6 months 25, 87 . The additional criteria are particularly relevant for patients without cytopenias, which frequently occurs in HCL after splenectomy or in HCLv; these patients often do not qualify for clinical trials until their disease is much more advanced. In relapsed patients, it is critical to determine if cytopenias are due to progressive disease or due to toxicity from prior treatment. A common mistake is to do a bone marrow biopsy too early after treatment and retreat the patient with chemotherapy if disease is detected. A patient in this situation will likely achieve CR without more treatment. This is the rationale for delaying post-treatment bone marrow biopsies until at least 4-6 months after the last treatment 25 . ESMO guidelines recommend delaying bone marrow until after 8-9 cycles of pentostatin 88 . Nevertheless, it may still be challenging to determine whether residual cytopenias and disease by bone marrow mean that treatment is required, or whether cytopenias are due to treatment toxicity and will resolve. For patients like this, flow cytometry of the blood at several time points can be useful; an increasing HCL count suggests that cytopenias are related to residual disease. On the other hand, undetectable HCL cells in blood often indicates a good response to the last treatment and suggests that cytopenias will resolve with additional time without further treatment. nodes >2cm in short axis can often occur due to persistent disease, and a PET scan or nodal biopsy can be helpful in these cases.

By consensus guidelines, progressive disease (PD) requires >25% worsening of cytopenias not due to toxicity, or >25% worsening of hepatosplenomegaly 25 . Other protocols including ours have included >50% increase in hepatosplenomegaly, >50% increase in circulating HCL cells, or >25% increase in adenopathy 91, 93, 102 . Patients not meeting criteria for CR, PR or PD are considered to have stable disease (SD).

6.1 First-line purine analog monotherapy. For the past >30 years, purine analog monotherapy has been considered the treatment of choice for HCL in 1 st line. While never compared head-tohead, pentostatin and cladribine are considered similar with respect to efficacy and toxicity, both achieving CR rates of 70-90% and treatment-free durations >10 years 17, 19, 21, [103] [104] [105] . Either can cause neutropenia and fever, mostly during the first month, particularly in patients with severe baseline neutropenia, but even in patients with neutrophil counts >1 x10 9 /L at baseline. Cladribine rashes are common 106, 107 . Reductions in CD4+ T-cells have been described with both agents lasting a median of 40-52 months 26, 27 . Neuropathy is seen in ~15% of patients after one course and can be both cumulative and delayed 19, 29, 90 . Cladribine became much more commonly used than pentostatin since it is administered over 5-7 days, while pentostatin is given every 2 weeks for 3-6 months. However, pentostatin may be preferable in high-risk patients who could use reduced doses initially and then return to full doses for later cycles 25 . On the other hand, cladribine can be given weekly, usually for 6 doses, to allow more gradual administration [108] [109] [110] . Two clinical trials randomized 100 and 132 cladribine-naïve HCL patients 1:1 to 5 daily vs 6 weekly doses of cladribine and showed similar efficacy without safety advantages to the weekly schedule 111, 112 . Cladribine is also effective subcutaneously and pharmacokinetic studies have documented adequate delivery [113] [114] [115] [116] [117] . When followed primarily by blood counts, patients relapse from CR at a median of ~15 years after 1 st -line purine analog 21 . Of 208 patients treated with cladribine (n=159) or pentostatin (n=49), the median relapse-free survival was 11 years 32 . However, patients up to 40 years of age, followed by bone marrow, were reported to relapse in <5 years 118 . There is no evidence showing plateau long term in failure-free survival to suggest cure for HCL patients 19, 21, 104, 105 . Of the original 358 patients treated with cladribine at Scripps 19 , 19 who were in continuous remission for a median of 16 years were studied, and bone marrow studies showed relapse in 3, MRD in 7, and MRD-free CR in 9 119 . In 34 patients randomized to cladribine alone, only 4 (12%) of the patients were in MRD-free CR at a median follow-up of 6.5 years 87 . Thus, cure after purine analog monotherapy, if possible, is unlikely at best. rituximab, compared to 0% at 6 months after cladribine or 3 months after rituximab, 64 . However, since many patients achieve CR 4-6 months after cladribine, the effect of rituximab could not be determined without a control group. We therefore performed a randomized trial of cladribine with rituximab begun on day 1 of cladribine or delayed at least 6 months later until MRD was detected in blood. Because rituximab was begun immediately rather than at 1 month, cladribine-rituximab (CDAR) synergy was possible based on the hypothesis that rituximab increases cell sensitivity to purine analog 121, 122 . Since purine analogs are cleared within 1-2 days, this type of synergy is not possible with delayed rituximab. At the 6-month time point, which was before delayed rituximab could be given, the CR rate was similar for CDAR, 34 (100%) of 34, and for cladribine monotherapy, 31 (91%) of 34, (p=0.24), but MRD-free CR was greatly improved, 33 (97%) vs 8 (24%) (p<0.0001). Moreover, as shown in Figure 1A , of 11 patients achieving MRD-free CR with cladribine alone, including 3 who became MRD-free after the 6-month time point, only 4 (12%) remained MRD-free at 6.5 years of median follow-up, compared to 32 (94%) of patients with CDAR (p<0.0001). Thus, immediate rituximab greatly improved the MRD-free CR rate and duration after cladribine. However, we found that delayed rituximab after cladribine alone achieved MRD-free CR in 14 (67%) of 21 patients. Figure 1B shows that of these 14 MRD-free patients after delayed rituximab, only 4 patients became MRD+ after delayed rituximab at a median of 6.5 years. We found that 32 (94%) vs 16 (47%) of patients (p=<0.0001) remained MRD-free after CDAR vs cladribine-delayed rituximab. Toxicity of CDAR in excess of cladribine was limited to transient thrombocytopenia, but CDAR was associated with higher neutrophil (p=0.017) and platelet (p=0.0015) counts at 4 weeks compared to cladribine monotherapy 87 . Compared to 28% of 90 historical patients who at 6.5 years relapsed from CR after purine analog with cytopenias requiring next therapy 21 , only 1 (1.4%) of 68 patients needed next therapy by a median of 6.5 years after CDAR or delayed rituximab (p<0.0001). Thus, not only MRD-free CR but also need for next treatment strongly favors CDAR or cladribine with delayed rituximab, compared with the standard of care approach of purine analog monotherapy without further therapy. The benefit of delayed rituximab is particularly relevant since so many thousands of patients have received cladribine alone and are MRD+ in blood. Thus, we believe that our data, combined with that of Ravandi et al, strongly argue that rituximab added to cladribine, either initially or delayed, be at least considered for 1 stline treatment of HCL. Some have recommended this combination approach for high-risk HCL 123 , and CDAR is now recommend as an option for 1 st line HCL treatment by the 2021 NCCN guidelines 124 . Results of CDAR suggest the potential utility of rituximab or other CD20 Mab combined with non-chemotherapy in 1 st -line HCL treatment, and this will be discussed below.

HCLv responds poorly to purine analog monotherapy and OS is 6-9 years compared to >25 years for classic HCL. [61] [62] [63] 65, 67, 125, 126 . Of 42 historical HCLv patients who received cladribine monotherapy, the CR rate was only 7% 20,126-130 . At MD Anderson Cancer Center, 7 HCLv patients received 1 st -line treatment with cladribine followed 4 weeks later by 8 weekly doses of rituximab with a CR rate of 86% and MRD-free CR rate of 71% 64, 120 . Two MRD-negative HCLv patients became MRD+ and the 5-year FFS and OS were 64.3% and 51.4%, respectively, at a median follow up of 60.2 months. OS was adversely affected by secondary malignancies 64, 120 . We reported phase 2 data for CDAR in patients with HCLv 65 131 , with a CR rate of 95% and MRD-free CR rate of 80% by bone marrow aspirate flow cytometry. Failure of CDAR to achieve MRD-free CR by 1 or 6 months, or the presence of TP53 mutations, was associated with decreased progression-free survival (PFS) and OS 131 . J o u r n a l P r e -p r o o f Based on these data, patients with HCLv should not be treated with purine analog monotherapy. We have also found that patients with unmutated IGHV4-34+ HCL respond poorly to purine analog monotherapy but, like HCLv, respond well to combinations of purine analog and rituximab 67, 132 . These cases are generally BRAF wild type 7 , and it has been reported that BRAF wild type HCL not responding purine analog monotherapy can respond well to purine analog-rituximab combinations 133 . Compared to CDAR, combinations of bendamustinerituximab 93 and pentostatin-rituximab are potentially more synergistic because more doses of rituximab are combined with purine analog. Therefore, we are testing bendamustine-rituximab vs pentostatin-rituximab in HCLv in both 1 st -line and later-line settings at NIH. This trial, along with other HCL/HCLv clinical trials listed on the HCL Foundation website, is shown in Table 1 and Figure 3 .

According to 2017 consensus guidelines, patients who relapse >2 years after first line purine analog monotherapy can be retreated with the same or alternate purine analog. Second-line purine analog therapy achieves CR rates of 62-69% 19, 21 . By bone marrow, 2 nd response duration is as short as 23 months 19 . In patients followed primarily by blood counts, median PFS of 9 years has been reported for 2 nd -line purine analog 21 . In general, repeated courses of purine analogs lead to decreasing efficacy and increasing cumulative toxicities, and the 2021 NCCN guidelines now list purine analog + rituximab rather than purine analog monotherapy for 2 nd line treatment 124 . Several studies have shown superior CR rates and durability after purine analog-rituximab in 2 nd line compared to the same purine analog given as monotherapy during 1 st -line 105, 120, 134 . Of 14 patients receiving cladribine followed 4 weeks later by rituximab in 2 nd -line, the CR rate was 100%, and MRD-free CR rate was 64% 120 . Cladribine with immediate vs delayed rituximab is currently being evaluated at NIH for patients with one prior course of purine analog (Table 1, Figure 3 ). In the 2021 NCCN guidelines, rituximab alone is listed as an option for patients who are intolerant of purine analog 124 . As a single-agent, rituximab achieved CR rates of 10-55% in 6 studies with a total of 97 patients [135] [136] [137] [138] [139] [140] , but of 51 patients with at least one prior purine analog and cytopenias requiring treatment, the CR rate was 20%. In the largest study with such patients, the CR rate was only 13% 137 , indicating that the activity of rituximab monotherapy in relapsed HCL is limited. Interferon can achieve responses in HCL 141 , but in the randomized trial with pentostatin, no patients crossing over from pentostatin to interferon achieved CR 17 . For patients with <2-year response to 1 st course of purine analog, NCCN guidelines now list vemurafenib 124 . The remainder of this review will focus on targeted therapies for multiply relapsed HCL, including recombinant immunotoxins targeted to the cell surface, one of which is FDA-approved for HCL.

Recombinant immunotoxins are chimeric proteins engineered to contain a protein toxin fused to a monoclonal antibody fragment 142 . Like antibody drug conjugates (ADC), they bind to cell surface receptors or antigens which internalize them, and the internalized molecule induces cell death. Unlike ADCs, where the toxic payload is a chemotherapeutic agent that the tumor may be resistant to, in recombinant immunotoxins the killing agent is a protein toxin that kills by arrest of protein synthesis due to ADP-ribosylation and inactivation of elongation factor-2 (EF2) 143, 144 . Protein synthesis arrest is associated with a decrease in MCL-1, and activation of BAK and the apoptotic cascade 145 . Plant toxins like ricin, J o u r n a l P r e -p r o o f which arrest protein synthesis by ribosomal inactivation, have been used to make chemical immunoconjugates, including one targeting CD22 146, 147 . Bacterial toxins like Pseudomonas exotoxin A (PE) and diphtheria toxin (DT) are advantageous for making recombinant toxins, since they are naturally made as single chains 148 . Humans are vaccinated against DT but not PE, which comes from Pseudomonas aeruginosa, so few patients have pre-existing antibodies able to neutralize PE-containing recombinant immunotoxins. These molecule are believed to kill by binding to host cells, unfolding in acidic endocytic vesicles 149 , undergoing furin proteolytic cleavage in the translocating domain between the ligand and toxin [150] [151] [152] , undergoing disulfide bond reduction liberating the toxin from the antibody fragment, 153 , trafficking the ADPribosylating toxin fragment to the endoplasmic reticulum 154 

Since CD22 greatly outnumbers CD25 in classic HCL, and HCLv as well as other B-cell malignancies express CD22 without CD25, 168 , anti-CD22 immunotoxins containing truncated PE were engineered, starting with chemical conjugates 169, 170 . The recombinant immunotoxin BL22 was engineered containing a disulfide stabilized Fv fragment binding to CD22 and connected to PE38 168, [171] [172] [173] . BL22 achieved CR rates of 47-61% in phase 1 and 2 HCL clinical trials [83] [84] [85] . An important toxicity observed was hemolytic uremic syndrome (HUS), not observed with LMB-2 or other recombinant immunotoxins containing PE38. It was completely reversible, occurred in 5-12% of HCL patients, and did not require plasmapheresis for complete resolution suggesting a mechanism different from Shiga-like toxin-induced HUS 174 .

To increase the activity and specificity of BL22, hot-spot mutagenesis created mutations in the complementarity determining region 3 (CDR3) domain of BL22 which were screened by phage display selection. A mutant containing THW instead of SSY at positions 100, 100a and 100b of the VH had 14-fold improved CD22 binding affinity, mainly due to slower off-rate 175 . The higher binding affinity led to a severalfold improvement in cytotoxicity toward both CLL and HCL. The mutant recombinant immunotoxin was first called HA22, then CAT-8015, and finally moxetumomab pasudotox (Moxe). Preclinical antitumor experiments showed improved activity compared to BL22 176 , and phase 1 clinical testing began May, 2007.

In the initial phase I report, 16 patients received 5-40 ug/kg every other day for 3 doses (QOD x3) per 28-day cycle, and 12 received 50 ug/kg 86 . There were 13 (46%) CRs, 10 (77%) of which remained in CR at a median of 29 months. The CR rate was not related to the number of prior courses of purine analog, but those with prior splenectomy (N=7) had no CRs, while 13 (62%) of 21 with spleens up to 325 mm had CR (p=0.007). This suggested that patients who are post-splenectomy have more advanced disease because they require more tumor infiltration into bone marrow to cause cytopenias severe J o u r n a l P r e -p r o o f enough for eligibility. For this reason, patients should receive Moxe prior to splenectomy. Grade 2 (moderate) HUS was documented in 2 patients (one at 30 and one at 50 ug/kg), limited to grade 1 thrombocytopenia and grade 1 creatinine elevations. These mild reversible laboratory abnormalities might not have been detected had patients not been watched for HUS. Grade 3-4 toxicities included grade 3-4 lymphopenia and leukopenia, probably representing treatment effect due to targeting leukemic and normal CD22+ B-cells. Common grade 1-2 toxicities included hypoalbuminemia, weight gain, edema, and proteinuria due to capillary leak syndrome (CLS). Transaminase elevations not impairing hepatic function were observed and were not considered dose-limiting per protocol. 8.6. Phase 1 efficacy of Moxe at the expansion dose level. The phase I study enrolled 21 more patients at 50 ug/kg, making a total of 33 at 50 ug/kg and 49 patients at all doses, without DLT or additional HUS cases 94 . Once achieving MRD-free CR including by bone marrow aspirate flow cytometry, patients could receive 2 additional (consolidation) cycles. Figure 2 shows response in the first patient at 50 ug/Kg QOD x3, who remains in MRD-free CR at the 12.5-year time point after CR. Of 33 patients at 50 ug/kg QOD x3, 21 (64%) achieved CR with ORR 88%. Of 20 CRs evaluable for MRD by all tests including bone marrow aspirate flow cytometry, 11 (55%) achieved MRD-free CR with only one relapse, and the other 10 remained in CR up to 72 months, with a median of 42 months. In contrast, of 9 patients with MRD+ CR, 8 relapsed, so median CR duration was significantly longer for MRD-free vs MRD+ CR (not reached vs 13.5 months p<0.0001). This was to our knowledge the first report that eradication of MRD in HCL is associated with longer CR duration, but there have been more since. The duration of MRD+ CR after >3 rd line treatment is much shorter than after 1 st -line HCL treatment with cladribine 87 , suggesting it is particularly important to eliminate MRD in multiply relapsed HCL.

Despite the immunogenicity of the bacterial toxin in Moxe, only 1 of 28 evaluable patients had high levels of neutralizing antibodies after cycle 1 86 . At 50 ug/Kg, 29 patients were evaluable for pharmacokinetic assays. Patient usually had low levels of Moxe after the 1 st dose because high CD22 density on HCL cells caused a CD22-sink effect. Because Moxe rapidly reduced tumor burden between the 1 st and 3 rd doses of cycle 1, peak levels and areas under the curve (AUC) increased, while volumes of distribution (Vd) and clearance decreased. In assays of antidrug antibodies (ADA), 15 evaluable patients had over 50% neutralization of 200 ng/ml of Moxe before cycles 2 (n=3), 3 (n=5), 4 (n=4),5 (n=2) and 6 (n=1), and hence became ineligible for retreatment. However, they did receive the last cycle because ADA levels were not known until after the cycle was completed. We found that peak levels and AUC increased while Vd and clearances decreased between days 1 and 5 of nearly all these cycles 94 . Thus, repeated doses of Moxe titrated out neutralizing antibodies and even the secondary immune response was inadequate in these patients to prevent therapeutic plasma levels of Moxe. In fact, 9 of these 15 patients achieved CR. Moreover, patients did not have side effects during production of ADA. These data justified retreatment with Moxe regardless of ADA and justified enrollment and retreatment during phase 3 pivotal testing without testing ADA.

Moxe was evaluated in an international phase 3 trial at 32 centers in 14 countries in relapsed/refractory HCL 91 . Patients required >2 prior treatments including >1 purine analog, and either rituximab, BRAF inhibitor or a 2 nd course of purine J o u r n a l P r e -p r o o f analog. Need for treatment included at least one cytopenia or painful spleen. A total of 80 HCL patients received Moxe at 40 ug/kg QOD x3 with cycles 28-days apart. Patients had to stop earlier than 6 cycles in the event of MRD-free CR, progressive disease, or unacceptable toxicity. Since MRD-free CR would make the patients ineligible for retreatment, we did not restage patients until end of the maximum 6 cycles. The 50 ug/Kg dose level during phase 1 was similar to 40 ug/kg during phase 3 due to improvements in purity. The primary endpoint was to achieve at least 28% of patients with 'durable CR', defined as CR followed by continued hematologic remission (HR) for over 180 days. Eighty patients were enrolled, ages were 34-84 (median 60) years, number of prior treatments were 2-11 (median 3), 18% had a BRAF inhibitor, 75% had rituximab, and 29% had purine analog-rituximab combinations 91 . Fifty (63%) patients completed all six cycles and 12 (15%) stopped early due to MRD-free CR, while 12 (15%) stopped early due to an adverse event which was treatment-related in 8 (10%) patients. At a median duration of follow-up of 24.6 months, the CR rate was 41% (33 of 80), ORR was 75%, and durable CR rate was 36% (29 of 80) 99 . Of the 4 patients who achieved CR but not durable CR, only 2 had recurrent cytopenias during the 180-day follow-up period, while 2 decided to travel and could not complete the monthly blood counts. Of the 33 CRs, 27 were MRD-free by IHC, and only 7 of these 27 relapsed, while 4 of 6 MRD+ CRs relapsed. Among the 6 patients with IHC-positive CR, median CR duration was 5.9 months vs not reached in the 27 who were MRD-free by IHC. Grade 3-4 toxicity occurred in 16.3% of the 80 patients, and lymphopenia (30%), HUS (5%), infection (2.5%), and CLS (2.5%) were observed. All CLS and HUS cases were reversible. There were 3 (3.8%) patients who died of infection, none Moxe-related. ADA were determined by ELISA assay 177 and ADA at baseline always involved antibodies binding to Moxe toxin domains 91 . Patients with CR had lower levels of ADA than those with PR, followed by stable disease and progressive disease 91 . ADA titers >10,240 were associated with higher clearances. Clinical benefit from Moxe was observed even in patients with low exposure or high ADA 178 . Based on the phase 1 and 3 data, Moxe was approved by the FDA in 2018, with the name Lumoxiti, indicated for patients with relapsed/refractory HCL after >2 prior systemic therapies, at least one of them a purine analog.

In phase 3 testing, CLS and HUS occurred in 5% and 7.5% of patients respectively 91, 99 . HUS in 7 HCL patients after BL22 and in 6 HCL patients after Moxe always presented on day 7 or 8, which is 2-3 days after the last dose of Moxe, and never presented after day 8 [83] [84] [85] [86] 91, 94 . Accordingly, we check labs on day 8 looking for increased creatinine, lactate dehydrogenase (LDH), and indirect bilirubin, and decreased hemoglobin, platelets, and haptoglobin. On the phase 1 trial, abnormal creatinine and platelets were limited to grade 1 severity, and either alone would not be considered HUS. It is possible that Moxe at high concentration binds to glomerular endothelium, possibly to an antigen other than CD22, exposing ultra-large multimers of von Willebrand's factor under the endothelial surface, which causes platelet aggregation and thrombin formation 174 . The hypothesis for Moxe binging to a glomerular antigen other than CD22 is based on lack of CD22 in that tissue and because HUS was not more common with Moxe than with BL22, despite the 14-fold improved binding affinity of Moxe vs BL22 for CD22 175 . The movement of fluid and protein out of the blood vessels occurring in CLS can cause intravascular volume depletion and hence an increase in Moxe concentration in the glomerular capillaries, increasing the risk of HUS. To prevent HUS, we keep the concentration of Moxe in the glomerulus low using oral hydration. While too much IV fluid leads to systemic and pulmonary edema, oral hydration is more rapidly regulated J o u r n a l P r e -p r o o f and prevents hypovolemia without worsening CLS. Since the capillary leaking is constant, we encourage patients to drink an average of 1 cup (250 ml) of water per hour from day 1 to 8 of each Moxe cycle. Patients should not go more than 3 hours at night without drinking. This requires patient education and monitoring 179 but it is well tolerated without even causing hyponatremia since the hydration is gradual. Headache, nausea and fever which can happen 6-24 hours after Moxe, can prevent patients from drinking, and these symptoms can be treated with dexamethasone 4 mg orally. Before these precautions using oral hydration and dexamethasone were instituted, 3 of 9 phase 3 patients had grade 3 HUS, vs only 1 case of grade 1 HUS in the next 17 patients (p=0.032 for grade 3 HUS). We have adopted these precautions to prevent toxicity from Moxe and permit more cycles of treatment to safely achieve MRD-free CR.

In a recent report, 3 patients were retreated with Moxe, two of them achieving CR and PR 180 . The responding patients had low levels of neutralizing antibodies from the phase 1 trial, were negative 12 years later prior to Moxe retreatment and became ADA-positive after retreatment. To increase the chance of MRD-free CR with Moxe, we are now testing Moxe with rituximab (Table 1, Figure 3 ). The rationale is that 1) rituximab depletes circulating B-cells for about 6 months after last dose, which may prevent ADA and increase plasma Moxe levels, and because 2) rituximab can reduce HCL volume, permitting Moxe to reach more HCL cells and hence achieve CR earlier. Although rituximab failed to prevent immunogenicity of LMB-1 targeting solid tumors 181 , it may prevent ADA in HCL since such patients have low humoral immunity compared to those with solid tumors. Also, LMB-1, unlike Moxe, has murine IgG constant domains 182 . In the phase 1 trial of Moxe-rituximab, the rituximab begins on day -2, 3 days before Moxe which is given days 1, 3 and 5. This allows rituximab time to clear normal B-cells and HCL burden prior to the 1 st dose of Moxe. On retreatment cycles spaced 28 days apart, rituximab can be given just prior to Moxe on day 1. Despite the above-mentioned disappointing results of rituximab monotherapy in relapsed HCL 137 , we reported that concurrent rituximab improves the MRD-free CR rate 6 months after cladribine from 24% to 97% 87 . This suggests that Moxe, which has more single-agent effectiveness than cladribine in achieving MRD-free CR, might be improved with rituximab. Rituximab was also able to dramatically improve the MRD-free rate of Vemurafenib from 0% 98 , to 57%, as reviewed below 95, 183 . The Vemurafenib-Obinutuzumab combination is currently being tested in 1 st -line (Table 1, Figure 3 ) and we believe Moxe-rituximab or Moxe-Obinutuzumab should be tested in 1 st line for HCL. Vemurafenib and other targeted agents with activity in HCL will now be reviewed.

9.1 BRAF in HCL and single agent targeting. The RAF-MEK-ERK signaling pathway mediates proliferation, differentiation, apoptosis and development in many cell types 184 . In 2011, Tiacci et al. reported that the BRAF V600E mutation, already observed in half of malignant melanomas, was detectable in nearly all classic HCL patients 4 . In the RAF-MEK-ERK pathway, BRAF V600E results in constitutive phosphorylation of MEK1 (encoded by MAP2K1), which then activates ERK by phosphorylation, leading to malignant proliferation 4, 6, 98 . Besides HCL and melanoma, other hematologic disorders carrying the V600E mutation include multiple myeloma 185 , Langerhans cell histiocytosis 186 , and Erdheim-Chester Disease 187 . BRAF lacks V600E (wild-type, WT) in patients with HCLv, unmutated IGHV4-34+ HCL, and J o u r n a l P r e -p r o o f some other classic HCL patients 7, 56, 188 . Vemurafenib, which has specificity for the BRAF V600E mutation and achieves improved OS in melanoma 189 , was reported to have clinical activity in HCL 190 . Clinical trials in Italy and in the US showed 35-42% CRs and ORR 96-100% 98 . Vemurafenib at 960 mg twice daily was administered for 8 weeks and was extended to 16-20 weeks if CR was not achieved by 8 weeks. Common toxicities were dermatologic and joint-related, including skin cancers. Responses occurred rapidly, particularly resolution of cytopenias 98, 190 . The median relapse-free survival in the Italian trial was 9 months for responders and 19 months for CRs, which were always MRD+ by BMBx IHC 98 . In a retrospective trial, reduced dose vemurafenib at 240 mg/day was effective in HCL with resolved cytopenias in 21 patients 191 . At 480 mg/day, vemurafenib showed complete inhibition of signalregulated kinase phosphorylation, and CR was achieved in 6 (40%) of 15 evaluable patients. Toxicities were still observed along with paradoxical ERK activation in BRAF WT cells 191 . Vemurafenib has been used as bridging therapy prior to definitive first-line therapy of HCL; due to its rapid reversal of cytopenias, vemurafenib was useful in a Jehovah's Witness HCL patient 192 , as well as 22 patients with deep neutropenia and high risk of toxicities to cladribine 193 . This strategy has been used during the COVID-19 pandemic to delay definitive immunosuppressive therapy in patients who would be at risk of adverse outcomes if infected with COVID-19 [192] [193] [194] . The BRAF V600E inhibitor dabrafenib achieved CR a patient with both HCL and melanoma 195 . Dabrafenib monotherapy, in a single-center pilot phase 2 trial in 10 patents with relapsed/refractory BRAF V600E+ HCL, achieved 3 (30%) CRs and 5 (50%) PRs for an ORR of 80% 196 . All 3 CRs had MRD by IHC, and one remained progression-free at 60.5 mo while the other progressed at 15.5 and 14, requiring therapy at 31 and 21 months. Patients had received dabrafenib for 12 weeks except for 1 CR who received 8 weeks of dabrafenib. Toxicities included arthralgias, facial flushing, warts, asymptomatic QTc prolongations, and elevations of hepatic and pancreatic enzymes. Fevers were not reported during the short course of treatment. 9.2 Targeting BRAF V600E and MEK. In melanoma, the combination of dabrafenib and the MEK inhibitor trametinib achieved longer median OS as compared with vemurafenib monotherapy, without an increase in toxicity, and in fact squamous cells cancers of the skin and keratoacanthomas were less frequent with dabrafenib-trametinib (1%) compared to vemurafenib (18%) 197 . The lower incidence of skin toxicity is consistent with downregulation by trametinib of the paradoxical activation of the MAPK pathway 197 . An international multicenter trial of dabrafenib and trametinib has completed accrual in HCL and other BRAF V600E+ histologies, and efficacy in anaplastic thyroid cancer led to FDA approval of the combination in that disease 198 . In HCL, dabrafenib-trametinib was reported to have significant clinical activity as reported at the 2018 American Society of Hematology Meeting. The combination of vemurafenib and cobimetinib is being tested in Europe, and the BRAF-MEK inhibitor combination encorafenibbinimetinib, approved for melanoma 199 , is being tested in HCL patients at NIH (Table 1, Figure  3 ). Patients WT for BRAF are generally ineligible for BRAF inhibitors but nevertheless may respond to MEK inhibition with trametinib monotherapy 200 . MEK inhibition with cobimetinib was reported to be effective in a patient resistant to vemurafenib because of reactivation of MEK-ERK signaling 201 . The MEK inhibitor binimetinib is currently being tested in patients with BRAF WT HCL and HCLv at NIH (Table 1, Figure 3 ).

Elimination of MRD with rituximab has been reported when used alone 87, 202, 203 or when J o u r n a l P r e -p r o o f combined with purine analogs 21, 64, 87, 105, 120, 134, 204 . To eliminate the MRD remaining with vemurafenib, 30 patients with relapsed/refractory HCL received vemurafenib 960 mg twice daily for 8 weeks with rituximab every other week for 16 weeks, including a 2-week break for restaging after the vemurafenib 95 . The CR rate was 87%, and the MRD-free CR rate was 57%. MRD in this study was detected by allele-specific PCR for the BRAF V600E mutation, which was sensitive to 0.05%. At a median of 34 months, of 26 patients with CR, 4 of 9 MRD+ CRs relapsed vs 0 of 17 MRD-negative CRs. Observed toxicities were as expected for each agent and no new safety signals for the combination were observed. An abstract with this data was published in 2019 183 before the COVID-19 pandemic. Thus, the potential of rituximab to interfere with immune response to either COVID-19 infection or vaccine was not a factor in accrual to this trial. A phase 2 trial combines obinutuzumab and vemurafenib for first line treatment of HCL, and this trial was interrupted somewhat by the COVID-19 pandemic (Table 1, Figure 3 ). Recently, 4 patients were reported who received vemurafenib and rituximab after prior Moxe 205 . One of these 4 patients achieved an MRD-free CR ongoing at 38 months, one relapsed from MRD-free CR at 13 months with massive splenomegaly and pancytopenia and could not achieve a 2 nd MRD-free CR with additional vemurafenib-rituximab, one had a hematologic remission for 18 months, and one died 3 weeks after vemurafenib with pneumonia and septic shock 205 .

B-cell receptor (BCR) signalling is important for the survival of HCL cells 206 . Molecules associated with the microenvironment like CXCR4, CCL3, CCL4, and CCL4 interact with the BCR and/or Bruton's Tyrosine Kinase (BTK) and affect HCL survival 207, 208 . The BTK inhibitor Ibrutinib is FDA approved for several B-cell malignancies including CLL and mantle cell lymphoma 209 . A case report of Ibrutinib treatment was noted in multiply relapsed HCLv 210 . Ibrutinib showed clinical benefit despite falling short of major response. A phase 2 multicenter trial of Ibrutinib (NCT01841723) was performed in 37 evaluable patients, 9 of whom were classified as HCLv and the rest as classic HCL 102 . Most patients began at 420 mg/day, and some of the 13 patients who started at 840 mg/day were dose-reduced to 420 due to toxicity. The primary endpoint was ORR which was 36% at 48 weeks, and 54% at best response. Responses improved with time, and eventually 7 (19%) achieved CR and 3 (8%) achieved MRD-free CR 102 . One of the HCLv patients with MRD-free CR had received HyperCVAD with rituximab and had positive cervical lymph nodes but negative blood and bone marrow. He was treated with 840 mg/day of ibrutinib, and it took 2.5 years for lymph nodes to become negative by exam. Since the patient remained negative by bone marrow and blood, he was considered an MRD-free CR once the cervical lymph nodes became non-palpable. The median PFS was not reached and at 36 months the PFS was 73%. Toxicity from Ibrutinib is generally less than for BRAF/MEK inhibitors, although 43% had hypertension and 16% had atrial fibrillation. Hematologic toxicities included anemia (43%), thrombocytopenia (41%), and neutropenia (35%). Non-hematologic toxicities included diarrhea (59%), fatigue (54%), myalgias (54%) and nausea (51%). Ibrutinib was combined with venetoclax for a patient with both IGHV4-34+ HCLv and CLL 211 , and ibrutinib plus BR was used to treat a patient with HCL 212,213 .

11.0 Treating HCL in the era of COVID-19. A review of 3377 patients showed that risk of death from COVID-19 was higher in patients with hematologic malignancies, particularly among patients hospitalized 214 . Clinical data on HCL patients infected with COVID-19 is limited. A J o u r n a l P r e -p r o o f case report describes a 54-year-old male with relapsed HCL 10 years after initial treatment who experienced respiratory failure from COVID-19 and had a difficult recovery 215 . A consensus document recommended caution in treating HCL patients with immunosuppressive agents during the COVID-19 pandemic, including both purine analogs which deplete T-cells and normal Bcells, and CD20 Mabs like rituximab which induce prolonged depletions of normal B-cells 216 . In addition to placing COVID-19 infected HCL patients at increased risk for adverse outcomes, immunosuppressive treatments pose a second potential problem, namely preventing effective vaccination. For this reason, the consensus document recommends that vaccinated HCL patients obtain antibody testing to confirm immunity 216 . It is known that rituximab prevents effective vaccination to influenza vaccine at least 6 months after the last dose 217 , but data are not yet available for HCL patients. In the CLL population, no patients exposed to anti-CD20 Mab within 12 months responded to the Pfizer COVID-19 vaccine 218 . Even BTK-inhibitors were associated with impaired response to COVID-19 vaccination in CLL 219 . A study of 1445 patients with hematologic malignancies immunized with either the Moderna (mRNA-1273) or Pfizer (BNT162b2) vaccine included 650 patients with CLL and 7 with HCL 220 . All 7 HCL patients achieved positive levels of antibodies, compared with only 64.2% of the patients with CLL. The treatment status of the patients was not reported, but it is possible that HCL patients, particularly several years after first line purine analog therapy, have good immunogenicity to COVID-19 vaccines. In the algorithm of different standard and investigational treatments shown in Figure  3 , the only agents without known risk of causing prolonged immunosuppression or preventing effective immunization would be Moxe, interferon and the BRAF and/or MEK inhibitors. The effect of Moxe on immunization should be minimal because of its short half-life 86, 91, 178 . In the phase 3 trial, Moxe decreased the number of normal B-cells much more transiently than would be expected from rituximab 91 . As mentioned above, it has been common during the pandemic for HCL patients to receive BRAF therapy even in 1 st line as a bridge to more definitive cladribine or cladribine-rituximab treatment and initiate definitive therapy only after documentation of effective vaccination. It has been assumed but not proven that BRAF inhibition is not immunosuppressive, and that such treatment may be appropriate for newly diagnosed HCL patients who can't achieve effective vaccination due to disease. How best to treat HCL patients who become infected with COVID-19 has not been reported. A recent cohort study reports 143 patients with hematologic malignancies who received convalescent plasma, with some suggestion of benefit 221 . Of these 143 patients, 123 (86%) had lymphoid malignancies, none reported as HCL. We anticipate clinical data to emerge soon regarding these important clinical issues, which remain relevant as the pandemic appears to continue.

Practice Points:  Patients with HCL and HCLv require a proper diagnosis including flow cytometry of the blood and bone marrow, and molecular testing when high-risk variants are suspected.  Patients with HCLv should not receive purine analog monotherapy, even in 1 st line.  Up to 6 months may be required for HCL treatment to achieve complete remission.

Therefore, the presence of residual disease and cytopenias within 4-6 months of treatment may not be an indication for retreatment; the cytopenias may be due to prior treatment and need more time to resolve.  Cladribine with immediate or delayed rituximab is indicated in 2 nd line treatment of HCL and is increasingly being used in 1 st line to eliminate minimal residual disease (MRD) and prevent relapse.

J o u r n a l P r e -p r o o f  Moxetumomab pasudotox (Moxe) is FDA-approved for at least 3 rd line treatment of HCL/HCLv, as it achieves MRD-free complete remission (CR) without chemotherapy toxicities. Adequate oral hydration during the first week of each cycle is important to prevent toxicities.  Therapies targeted to BRAF, MEK and BTK have shown utility in treating relapsed HCL, and BRAF inhibition combined with CD20 Mab can achieve MRD-free CR.  Prevention of effective immunization may occur due to HCL/HCLv comprising most or all B-cells or can occur from purine analogs, CD20 Mabs, or BTK inhibitors. Antibody testing is recommended in HCL to document effective vaccination, particularly to COVID-19, and particularly before beginning immunosupressive therapies.

Research Agenda:  Like vemurafenib-rituximab in relapsed HCL, vemurafenib-obinutuzumab can achieve MRD-free CR in 1 st line, where it is being tested.  Moxe combined with rituximab is under investigation to achieve MRD-free CR more quickly with lower risk of anti-drug antibodies (ADA). There is interest in testing this combination in 1 st line.  While BRAF inhibition cannot be used in HCLv, clinical trials are underway in HCLv testing Moxe-rituximab, the MEK inhibitor binimetinib, and CAR-T cell therapy targeting CD22.

Future considerations:  To move the field of HCL/HCLv forward, more patients should be encouraged to participate in clinical trials. Many trials can be done without frequent travel. With more clinical data, treatment recommendations will become more evidence-based

Leukemic reticuloendotheliosis

Leukemic reticuloendotheliosis (hairy cell leukemia)

Cancer Statistics, 2021

BRAF mutations in hairy-cell leukemia

Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation

Genomics of Hairy Cell Leukemia

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

Hairy Cell Leukemia and Ground Water Contamination With Industrial Solvents: a Case Report

Three cases of hairy cell leukemia in coal miners

Exposure to pesticides as risk factor for non-Hodgkin's lymphoma and hairy cell leukemia: pooled analysis of two Swedish case-control studies

Hairy cell leukemia and bladder cancer in a patient: relation with dye exposure and review of the literaure

Epidemiology and environmental risk in hairy cell leukemia

Hairy cell leukemia: a clinical review based on 71 cases

Alpha interferon for induction of remission in hairy-cell leukemia

Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin)

The treatment of hairy-cell leukaemia with 2'-deoxycoformycin

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study

Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine

Long-term follow-up of patients with hairy cell leukemia after cladribine treatment

2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

Cladribine in the treatment of hairy-cell leukaemia

Long-term results in hairy cell leukemia treated with pentostatin

NCCN Clinical Practice Guidelines in Oncology

Consensus Guidelines for the Diagnosis and Management of Patients with Classic Hairy Cell Leukemia Blood

2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia

Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up

Purine analog toxicity in patients with hairy cell leukemia

Neurotoxicity of purine analogs: a review

Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia

Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

Clinical features and diagnosis of hairy cell leukemia

Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report

Autoimmune disease in hairy-cell leukaemia: clinical syndromes and treatment

Vasculitides in hairy cell leukemia

Treatment-Induced Aggravation of Vasculitis in Hairy-Cell Leukemia

Skin changes in hairy cell leukemia

Bone lesions in hairy cell leukemia: Diagnosis and treatment

Multifocal osteolytic lesions in hairy cell leukemia-the importance of PET/CT in diagnosis and assessment

Hairy cell leukemia: an autopsy study

The hairy cell leukaemia oxymoron: monocytotic monocytopenia

Distinguishing Hairy Cell Leukemia Variant from Hairy Cell Leukemia: Development and Validation of Diagnostic Criteria

Bone marrow and splenic histology in hairy cell leukaemia

An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia

Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1)

Evaluation of allelespecific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia

The Usefulness of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow

The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia

A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes

Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion

Recurrent CDKN1B (p27) mutations in hairy cell leukemia

BRAF V600E mutation in hairy cell leukemia: from bench to bedside

Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia

Class II human leukocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uremic syndrome

A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia

Immunophenotyping and differential diagnosis of hairy cell leukemia

Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant

Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?

Hairy cell leukaemia-variant: Disease features and treatment

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy

Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?

Molecular variant of hairy cell leukemia with poor prognosis

Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variant

High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias

Hairy cell leukemia with CCND1/IGH fusion gene and BRAF V600E mutation

Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy

CD5 positive hairy cell leukemia: A rare case report with brief review of literature

Marked retroperitoneal lymphadenopathy in hairy cell leukemia: a case report

Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues

CD10-Positive Hairy Cell Leukemia Involving Multiple Deep Lymph Nodes

Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience

Responses in refractory hairy cell leukemia to a recombinant immunotoxin

LMB-2) in patients with hematologic malignancies

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

Randomized phase II study of 1st-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia

Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

Differential expression of CD43, CD81 and CD200 in classic versus variant hairy cell leukemia

Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia

Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): Long-term follow-up from the pivotal Phase 3 trial

An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy

Soluble CD22 as a Tumor Marker for Hairy Cell Leukemia

Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

Long-term follow-up after purine analogue therapy in hairy cell leukaemia

Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review

Atypical features of cutaneous adverse drug reactions during therapy for hairy cell leukemia

Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia

Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complications

Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial

Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)

Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia

Pharmacokinetics of 2-chloro-2 '-deoxyadenosine administered subcutaneously or by continuous intravenous infusion

Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study

Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial

Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

In vitro induction of apoptosis of neoplastic cells in lowgrade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases

The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant

Hairy Cell Leukemia, Version 2.2021 NCCN Clinical Practice Guidelines in Oncology

Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience

The natural history and clinicopathological features of the variant form of hairy cell leukemia

Phase II clinical study of cladribine in the treatment of hairy cell leukemia

Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases

Treatment of hairy cell leukemia-variant with cladribine

Urbanska-Rys H. Hairy cell leukemiavariant treated with 2-chlorodeoxyadenosine--a report of three cases

Long term follow-up of a phase II study of cladribine with concurrent rituximab in patients with hairy cell leukemia variant

Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report

A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin

Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence

Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia

Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia

Rituximab in relapsed or refractory hairy cell leukemia

Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab

Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)

Long-term treatment of hairy cell leukemia with interferon-alpha: still a viable therapeutic option

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox

Immunotoxin therapy of cancer

Immunotoxins in the treatment of refractory hairy cell leukemia

Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1

A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

Getting plant toxins to fuse

Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity

Cell-mediated cleavage of Pseudomonas exotoxin between Arg 279 and Gly 280 generates the enzymatically active fragment which translocates to the cytosol

Characterization of a cellular protease that cleaves Pseudomonas exotoxin

Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver

Reduction of furin-nicked Pseudomonas exotoxin A: An unfolding story

Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor

Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes

The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion

Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development

Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin

Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1

Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies

Induction of Caspase-Dependent Programmed Cell Death in B-Cell Chronic Lymphocytic Leukemia Cells by Anti-CD22 Immunotoxins

A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds

Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma

The recombinant immunotoxin anti-Tac(Fv)-Pseuodomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia

Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia

Hairy cell leukemia, a B-cell neoplasm which is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2)

Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias

Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice

Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity

Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells

Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys

Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome

Improved Cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display

CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies

A novel approach to assess domain specificity of antidrug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains

Population Pharmacokinetics, Efficacy, and Safety of Moxetumomab Pasudotox in Patients With Relapsed or Refractory Hairy Cell Leukemia

Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia

Moxetumomab pasudotox as retreatment for heavily-pretreated relapsed hairy cell leukemia

Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1

Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin

The BRAF inhibitor vemurafenib plus rituximab produces a high rate of deep and durable responses in relapsed/refractory hairy cell leukemia: updated results of a phase-2 trial

RAF-MEK-ERK pathway in cancer evolution and treatment

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis

BRAF Mutations in Erdheim-Chester Disease

Hairy cell leukemia-new genes, new targets

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

BRAF inhibition in refractory hairycell leukemia

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah's Witness patient

Inhibitor of BRAF(V600E) Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications

BRAF inhibitor treatment in classic hairy cell leukemia: a longterm follow-up study of patients treated outside clinical trials

Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

Improved overall survival in melanoma with combined dabrafenib and trametinib

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia

Targeting MEK in vemurafenib-resistant hairy cell leukemia

Rituximab as treatment for minimal residual disease in hairy cell leukaemia

Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up

Eradication of minimal residual disease in hairy cell leukemia

Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox

Hairy cell leukaemia: biological and clinical overview from immunogenetic insights

The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

Ibrutinib in CLL and B Cell Malignancies. Leuk Lymphoma

Ibrutinib for relapsed refractory hairy cell leukemia variant

Biclonal IGHV-4-34 hairy cell leukemia variant and CLL -successful treatment with ibrutinib and venetoclax

Novel therapeutics in the treatment of hairy cell leukemia variant

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Janus-faced course of COVID-19 infection in patients with hematological malignancies

Hairy Cell Leukemia and COVID-19. Adaptation of Treatment Guidelines

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Acknowledgements: The authors recognize the contributions of clinical and research staff of the Laboratory of Molecular Biology Clinical Immunotherapy Section. The following resources contributed to the work at NIH mentioned in the review: The NIH Intramural Program and research support from AstraZeneca, Novartis, Genentech, Teva, and Pfizer.Conflict of Interest. RJK is a coinventor on the NIH patent for Moxe.